# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: modern shifted

## Reason for visit

New patient with six weeks of drooping eyelids, double vision and fatigable weakness while recovering from a car crash: examination, ice pack test, breathing measurements, baseline tests, a pyridostigmine trial, kidney screening, and neuromuscular neurology referral. **S**

## Historical basis

- Wilma Pearl Mankiller was born on November 18, 1945, in Tahlequah, Oklahoma, the capital of the Cherokee Nation, the sixth of eleven children; her father was a full-blood Cherokee. A Cherokee Nation release gave her birthplace as the W.W. Hastings Indian Hospital in Tahlequah; the Oklahoma Hall of Fame says she was born at Rock Mountain in Adair County. **D**
- As a child she moved with her family from Mankiller Flats in Adair County to San Francisco under the Bureau of Indian Affairs relocation program (1956 or 1957 by different accounts); she later described the move as her own little Trail of Tears. **D**
- The occupation of Alcatraz Island in 1969 and her work with American Indian communities in California in the 1970s set the course of her activism. **D**
- She returned to eastern Oklahoma with her two daughters in the later 1970s (1976 or 1977 by different accounts), worked for the Cherokee Nation, and lived on her grandfather's allotment, Mankiller Flats, in Adair County. **D**
- In 1979 she was nearly killed in a head-on car crash on a curve, in which the driver of the other car, one of her best friends, died. She needed about 17 operations; accounts say her leg was barely saved from amputation and that she was told she might never walk again. The Oklahoma Hall of Fame dates the crash to 1978 and describes shattered legs, broken ribs and a crushed face. **D**
- Her recovery was made harder by the emotional trauma of her friend's death in the crash. **D**

8 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to know why her eyelids droop and her arms give out, after a year of hard recovery. **S**
- She wants to keep working for her community. **S**
- She wants care that respects her as a Cherokee woman, close to home where possible, with her own medicine respected. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1979 (1978 in one account): Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and face **D** (CLM-0005)

## Procedures and immunizations

- 2026-03-09 to 2026-03-09: Bedside measurement of breathing: negative inspiratory force -70 cm H2O, single-breath count to 32, with the seated FVC **S**
- 2025-06-12: Tdap vaccine, at the hospital after the crash **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 12.8 g/dL; White cell count: 6.9 10*3/uL; Platelets: 262 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Glucose: 88 mg/dL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 2021): 102 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; AST: 21 U/L; Albumin: 4.2 g/dL; TSH: 1.9 mIU/L; Hemoglobin A1c: 5.3%; Urine albumin-to-creatinine ratio: 14 mg/g; 25-hydroxyvitamin D: 31 ng/mL; Forced vital capacity (seated): 3.3 L; PHQ-9: 7. All results are synthetic.

BP 126/82 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 61.8 kg; BMI 23.3 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, direct and composed; tired; speaks of the hard year since the crash and the loss of her friend; PHQ-9 score 7. Functional status: Independent in daily activities; walks without help indoors and with a cane on rough ground after the leg operations; by evening she tires holding her arms up to brush her hair and must rest her jaw while eating. Physical examination is intentionally limited. **S**

## Assessment

1. Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected; status draft. **S**
2. Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged; status draft. **S**
3. Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground; status draft. **S**

## Plan

- Neuromuscular neurology consultation within two weeks for suspected generalized myasthenia gravis: diagnosis, immunotherapy, thymectomy and safety. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026) **S**
- Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs. Guideline: KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025) **S**
- Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) **S**

## Guideline basis

- Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020), Myasthenia Gravis Foundation of America task force (Neurology)
- Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016), Myasthenia Gravis Foundation of America task force (Neurology)
- Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026), Myasthenia Gravis Foundation of America
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025), Kidney Disease: Improving Global Outcomes (KDIGO)
- Cherokee Nation Health Services (2026), Cherokee Nation
